CD20 (N) (4-6H:2C) Anti-Human Mouse IgG MoAb

Rituximab used for treatment of lymphoma is an antibody drug of which target is pan-B cell marker, CD20. It has been reported that the C-terminal region of CD20 undertakes a critical role in a binding to rituximab and the association between C-terminal mutations and rituximab-resistance has been investigated. This antibody was developed as a new monoclonal antibody that recognizes the N-terminal region of CD20 molecule to detect comprehensive CD20 regardless of C-terminal mutations. It is expected to be useful for the detailed examination of CD20 molecules by adding this antibody to reserch of CD20.
List Price: $517
  • Buy 5 for $491.15 each and save 5%
  • Buy 21 for $465.3 each and save 10%
  • Buy 31 for $439.45 each and save 15%
  • Buy 51 for

Properties

Data Sheet Click for Datasheet
Catalog Number MA01151
Size 100 μg
Host Type Mouse
Immunogen Synthetic peptide of the N-terminal part of human CD20 (CMQSGPKPLFRRMSS).
Specificity
Isotype IgG3
Reacitivity Human
Clone 4-6H:2C
Uniprot
Concentration Please see datasheet.
Dilution
Formulation Lyophilized product from 1.0 mL of PBS containing 1 % BSA and 0.05 % NaN3
Application IHC, WB.
Other Names
Storage Lyophilized product: 5 years at 2 - 8°C; Solution: 2 years at -20°C.
Postscript For research use only, not for use in diagnostic procedures.

© Copyright 2024 TZYBIOTECH. All Rights Reserved. SiteMap